2025
The Impact of Cognitive Impairment on Cardiovascular Disease
Jamil Y, Krishnaswami A, Orkaby A, Stimmel M, Brown Iv C, Mecca A, Forman D, Rich M, Nanna M, Damluji A. The Impact of Cognitive Impairment on Cardiovascular Disease. Journal Of The American College Of Cardiology 2025, 85: 2472-2491. PMID: 40562512, DOI: 10.1016/j.jacc.2025.04.057.Peer-Reviewed Original ResearchConceptsImpact of cognitive impairmentCognitive impairmentCardiovascular diseaseHealth care utilizationOlder adult populationEvidence-based management strategiesMedical adverse eventsHealth literacyCare utilizationOlder adultsMitigate cognitive impairmentUnder-prescribedReduced participationU.S. populationTreatment of patientsAdult populationGuideline-directedExcess morbidityCardiac patientsRisk factorsOlder patientsAdverse eventsHealthMechanism of cognitive impairmentInterventional managementLong-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.
Levy C, Trivedi P, Kowdley K, Gordon S, Bowlus C, Londoño M, Hirschfield G, Gulamhusein A, Lawitz E, Vierling J, Mayo M, Jacobson I, Kremer A, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter C, Crittenden D. Long-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. The American Journal Of Gastroenterology 2025 PMID: 40553148, DOI: 10.14309/ajg.0000000000003603.Peer-Reviewed Original ResearchPrimary biliary cholangitisMonths of treatmentNumerical rating scaleLong-term efficacyBiliary cholangitisResponse ratePruritus Numerical Rating ScaleSerious adverse eventsYear of treatmentInterim study resultsComposite response rateInterim cutoffLong-term useOpen-labelPlacebo-controlledPlacebo-treatedTrial patientsAdverse eventsSeladelparPatientsResponse completenessAssurance studyCholangitisMonthsRating ScaleSulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin S, Gupta J, Das A, Gupta K, Dunne M. Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection. NEJM Evidence 2025, 4: evidoa2400414. PMID: 40552968, DOI: 10.1056/evidoa2400414.Peer-Reviewed Original ResearchConceptsUrinary tract infectionUncomplicated urinary tract infectionsIntent-to-treat populationSusceptible to amoxicillin/clavulanateTract infectionsUrine cultureAdverse eventsTreatment of uncomplicated urinary tract infectionsCombined population of patientsPatients treated with amoxicillin/clavulanateTreatment-emergent adverse eventsBaseline urine culturePositive urine cultureMild adverse eventsPopulation of patientsTreatment of adult womenClasses of antibioticsMicrobiological eradicationBaseline pathogensClinical cureDouble-blindMedian ageTrial medicationAmoxicillin/clavulanateAntimicrobial resistanceOnce-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Jastreboff A, Ryan D, Bays H, Ebeling P, Mackowski M, Philipose N, Ross L, Liu Y, Burns C, Abbasi S, Pannacciulli N. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. New England Journal Of Medicine 2025 PMID: 40549887, DOI: 10.1056/nejmoa2504214.Peer-Reviewed Original ResearchBaseline to weekDose escalationTreatment of obesityTreatment policy estimandType 2 diabetesObese cohortBody weightDose-ranging trialPhase 2 trialGastrointestinal adverse eventsGlycated hemoglobin levelsPeptide-antibody conjugatesGlucagon-like peptide-1 receptor agonismIntention-to-treat approachOnce-monthlyDouble-blindPlacebo groupPlacebo-controlledReceptor antagonismReceptor agonismHemoglobin levelsAdverse eventsPlaceboSafety signalsObesityAmycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff A, Key C, Petersen S, Vegge A, Adelborg K. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet 2025 PMID: 40550231, DOI: 10.1016/s0140-6736(25)01185-7.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsAmylin receptor agonistAdverse eventsGLP-1Receptor agonistsTreatment durationPlasma concentration-time curvePhase 1b/2a studyConcentration-time curveMaximum plasma concentrationEarly-phase studiesClinical Research CentreRandomised controlled studyProportion of discontinuationBaseline bodyweightPart BTolerability profileMaintenance dosePlacebo-controlledGastrointestinal eventsPrimary endpointSecondary endpointsFull analysisWeight loss propertiesPlasma concentrationsUltrasound‐Guided Nerve Block for Pediatric Femur Fractures in the Emergency Department: A Prospective Multi‐Center Study
Binder Z, Ng C, Klekowski N, Lawson S, Riera A, Toney A, Pade K, Saint The T, Shaahinfar A, Chaudoin L, Lauer E, Snelling P, Moake M. Ultrasound‐Guided Nerve Block for Pediatric Femur Fractures in the Emergency Department: A Prospective Multi‐Center Study. Academic Emergency Medicine 2025 PMID: 40524602, DOI: 10.1111/acem.70084.Peer-Reviewed Original ResearchPediatric emergency medicineFascia iliaca compartment nerve blockEmergency departmentPediatric femur fracturesFemur fracturesPain intensityPediatric emergency medicine physiciansSelf-reported pain intensityFaces Pain Scale-RevisedFracture pain managementPain scoresChildren aged 4Pain score reductionEmergency medicinePost-enrollmentAdverse eventsNerve blockPain managementSecondary outcomesOpioid medicationsPrimary outcomeOral morphine equivalentsProcedure useUltrasound-guided nerve blockProspective multi-center studyImmune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Wolf D, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Investigators I, Symmans W, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin E, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van ‘t Veer L, Mukhtar R, Melisko M, Wallace A, Yeung K, Albain K, Robinson P, Lo S, Olopade F, Potter D, Beckwith H, Blaes A, Boughey J, Haddad T, Elias A, Isaacs C, Mitri Z, Kemmer K, Lu J, Lang J, Thomas A, Trivedi M, Hershman D, Meisel J, Kalinsky K, Vaklavas C, Williams N, Ellis E, Sanford A, Sanft T, Viscusi R, Arora M, Falkson C, Northfelt D, Murthy R, Haley B, Yung R, Mayer I, Khan Q, Edmiston K. Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precision Oncology 2025, 9: e2400776. PMID: 40526879, PMCID: PMC12184982, DOI: 10.1200/po-24-00776.Peer-Reviewed Original ResearchConceptsPCR ratePredicting pathologic complete responseTriple-negative breast cancerNeoadjuvant immunotherapyTumor gradeHormone receptor-positive early-stage breast cancerHuman epidermal growth factor receptor 2-negativeBreast cancerEarly-stage triple-negative breast cancerImmune-related adverse eventsControl armEarly-stage breast cancerMammaPrint-high riskHormone receptor-positivePathological complete responseResponse to IOI-SPY2 trialStandard of careER-lowComplete responseNeoadjuvant therapyReceptor-positiveHER2+I-SPY2Adverse eventsSustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
Bernstein J, Betschel S, Busse P, Banerji A, Wedner H, Manning M, Zaragoza-Urdaz R, Anderson J, Gagnon R, Baptist A, Soteres D, Lumry W, Craig T, Petroni D, Hsu F, Nova Estepan D, Juethner S, Watt M, Khutoryansky N, Zuraw B. Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study. Advances In Therapy 2025, 1-20. DOI: 10.1007/s12325-025-03226-3.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsLong-term prophylaxisHereditary angioedemaHAE attack ratesPost-baseline safety assessmentProphylaxis of hereditary angioedemaConclusionReal-world dataInjection site reactionsAttack rateReal-world studyYears of ageFemale patientsLanadelumabSite reactionsAdverse eventsFollow-upSafety signalsSafety dataEMPOWER studyPatientsDeficiency typeAngioedemaLow attack rateSustained effectPost-baselineSafety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
Gambardella V, Accordino M, Bedard P, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman J, Juric D, Jhaveri K. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open 2025, 10: 105303. PMID: 40513140, PMCID: PMC12205636, DOI: 10.1016/j.esmoop.2025.105303.Peer-Reviewed Original ResearchHER2-negative advanced breast cancerAdvanced breast cancerAdverse eventsCombination therapyPIK3CA-mutationsBreast cancerHormone receptor (HR)-positiveDiscontinued study treatmentBreast cancer therapyLong-term toleranceDose reductions/interruptionsAny-gradeData cutoffDose modificationTolerability profileHR-positiveProgressive diseaseStudy treatmentMetformin treatmentCancer therapyNo treatmentPatientsRisk factorsTherapyHyperglycemiaConsensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Kang B, Cohen J, Geronemus R, Kilmer S, Ross E, Tanzi E, Waibel J, Wong B, Alam M, Alexiades M, Arndt K, Avram M, Bhatia A, Biesman B, Bloom J, Burns A, Chan H, DiGiorgio C, Dover J, Fathizadeh S, Esteves S, Gold M, Goldberg G, Haedersdal M, Hoss E, Ibrahimi O, Jalian H, Kelly K, Manuskiatti W, Marks L, Munavalli G, Pozner J, Robb C, Rossi A, Saedi N, Shumaker P, Stankiewicz K, Wanner M, Wu D, Wulkan A, Ortiz A. Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face. Lasers In Surgery And Medicine 2025 PMID: 40495549, DOI: 10.1002/lsm.70035.Peer-Reviewed Original ResearchAblative laser resurfacingLaser resurfacingAdverse eventsPostoperative careConsensus statementPlastic surgeryManagement of adverse eventsContraindications to treatmentManagement of infectionsConsensus meetingManagement of complicationsExpert clinical experienceManagement of scarsInternational consensus statementFacial plastic surgeryIntraoperative precautionsPatient selectionOculoplastic surgerySurgeryClinical experiencePreoperative careLaser surgeonVirtual consensus meetingSystematic reviewDraft statementGlucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease
Lee S, Yin L, Xiao N, Rhee T, Lo H, Wong S, Fox S, Teopiz K, Lam B, Zheng Y, Le G, Mansur R, Rosenblat J, McIntyre R. Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease. CNS Spectrums 2025, 30: e44. PMID: 40485141, DOI: 10.1017/s109285292510031x.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAsCentral nervous systemReceptor agonistsEvidence of clinically meaningful benefitFood and Drug Administration (FDA)-approved treatmentsTreatment-emergent adverse eventsParkinson's diseaseEffects of GLP-1RAsEmergent adverse eventsClinically meaningful benefitFDA-approved treatmentClinical trial evidenceNo current therapyTreatment of Parkinson's diseasePreclinical evidenceAdverse eventsCurrent therapiesMeaningful benefitClinical evidenceFeatures of PDTherapeutic benefitTrial evidenceInsulin resistanceStandardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors
Raskin N, Hiligsmann M, Rebutoc A, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall D, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood G. Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors. Seminars In Arthritis And Rheumatism 2025, 74: 152769. PMID: 40544704, DOI: 10.1016/j.semarthrit.2025.152769.Peer-Reviewed Original ResearchHealth outcome descriptorsPatient decision aidsHealth outcomesPatient-important outcomesPatient preference studiesOutcome descriptorsThematic content analysisOutcome descriptionsNarrative summaryPreference studiesPtDAsRA outcomesAuthor consensusRheumatoid arthritisData extractionModifying drug therapySymptoms patientsContent analysisAdverse eventsDrug therapyDisease modifying drug therapyLack of descriptionHealthOutcomesAIDSMulti-Center Experience with Unitary Stent Graft System for Endovascular Debranched Aortic Repair of Various Thoracoabdominal Aortopathies
Pupovac S, Restrepo-Espinosa V, Chen J, Zaky M, Answini G, Kelly P, Vallabhajosyula P, Nassiri N. Multi-Center Experience with Unitary Stent Graft System for Endovascular Debranched Aortic Repair of Various Thoracoabdominal Aortopathies. The Annals Of Thoracic Surgery 2025 PMID: 40484210, DOI: 10.1016/j.athoracsur.2025.05.026.Peer-Reviewed Original ResearchThoracoabdominal aortic aneurysmsAortic repairOpen surgeryTechnical successAortic aneurysmPatency ratesShort-neck infrarenal aneurysmsTarget vessel patency rateMedian hospital stayThirty-day mortalityClinical follow-upMajor adverse eventsStent graft systemMulti-center experienceMulti-center studyMedian followChronic dissectionInfrarenal aneurysmsReintervention rateEndoluminal bypassInfrarenal EVARThirty-dayStent graftHospital stayAdverse eventsPRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
Dragnev K, Redman M, Reckamp K, Khalil M, Henick B, Moon J, Ahmadzai P, LeBlanc M, Carrizosa D, Hesketh P, Sigal E, Allen J, Saltos A, Faller B, Herbst R, Blanke C, Gray J. PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. Journal Of Clinical Oncology 2025, 43: lba8671-lba8671. DOI: 10.1200/jco.2025.43.17_suppl.lba8671.Peer-Reviewed Original ResearchSquamous cell carcinomaOverall survivalAdvanced NSCLCRecurrent non-small cell lung cancerRandomized phase III trialMedian of follow-upNon-small cell lung cancerPhase II randomized studyInterim analysisTreated with ICIPlatinum-based therapyTreated with immunotherapyPhase III trialsCell lung cancerLong follow-upStandard of careChemotherapy-freeHistological subgroupsNon-SCCIII trialsCell carcinomaMedian ageToxicity profileRandomized studyAdverse eventsORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Riess J, de Langen A, Ponce S, Goldberg S, Piotrowska Z, Goldman J, Le X, Cho B, Yoneshima Y, Ambrose H, Cavazzina R, Tang K, Lau J, Yu H. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology 2025, 9: e2400818. PMID: 40466026, DOI: 10.1200/po-24-00818.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerLung cancerEpidermal growth factor receptor alterationsFirst-line osimertinibSafety of osimertinibProgression-free survivalDuration of responseNovel drug combinationsData cutoffPartial responseOsimertinib resistanceRisk-benefit analysisOverall survivalReceptor alterationsDiscontinued treatmentInvestigator assessmentClinical benefitNecitumumabSafety profileOsimertinibReport final resultsAdverse eventsDrug combinationsLong-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
Medina T, Chesney J, Kluger H, Hamid O, Whitman E, Cusnir M, Thomas S, Wermke M, Domingo-Musibay E, Phan G, Kirkwood J, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik A, Curti B, Kim K, Daniels G, Wilson M, Lee S, Puzanov I, Harker-Murray A, Logan T, Simon J, Thomas I, Schuler-Thurner B, Moritz R, Hassel J, Grigoliet G, Arance A, Rubio B, Rodriguez J, Berrocal A, de Sanmamed M, Arkenau H, Evans T, Corrie P, Dalle S, Bedane C, Olah J, Orcurto A. Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study. Journal Of Clinical Oncology 2025, 101200jco2500765. PMID: 40454684, DOI: 10.1200/jco-25-00765.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesOverall survivalLong-term efficacyCell therapyMedian duration of responseLow tumor burdenMedian overall survivalDuration of responseTumor burden reductionLong-term safety concernsBRAF/MEK inhibitorsAdvanced melanomaBrain metastasesImmune checkpointsTumor burdenMedian durationSafety profileAdverse eventsTreatment optionsInterleukin-2Follow-upLong-term benefitsOverall populationPatientsCutoff dateThe Morbidity, Mortality, and Improvement Conference: An Innovative, Action-oriented Learning Space
Dickinson J, Placide S, Magier S, Merchant N. The Morbidity, Mortality, and Improvement Conference: An Innovative, Action-oriented Learning Space. The Joint Commission Journal On Quality And Patient Safety 2025 DOI: 10.1016/j.jcjq.2025.06.008.Peer-Reviewed Original ResearchSafety cultureImprovement ConferenceHealth System ChangeClosed-loop communicationAction itemsSafety reportsInterprofessional teamworkInterprofessional audienceTraditional morbidityMortality conferencesAdverse eventsPerceived impactSafety attitudesIncreased comfortStaffAttendee surveysDiverse staffSystem improvementPlanning groupConference attendanceInteractive discussionInterdisciplinary collaborationPsychological safetySystem changesSystem-level solutionsPhase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC).
Bhatia A, Wei W, Chiorazzi M, Deshpande H, Reynolds J, Gehan D, Tara H, Newton B, Verma A, Sayed Z, Roche A, Mehra S, Judson B, Yarbrough W, Burtness B. Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC). Journal Of Clinical Oncology 2025, 43: 6023-6023. DOI: 10.1200/jco.2025.43.16_suppl.6023.Peer-Reviewed Original ResearchHead and neck squamous cell cancerEpidermal growth factor receptorMedian overall survivalCombination of cetuximabAdverse eventsHuman epidermal growth factor receptor (HER)-2Recurrent/metastatic head and neck squamous cell cancerRefractory to platinum-based chemotherapyEpidermal growth factor receptor targetEpidermal growth factor receptor inhibitionSingle-arm phase II trialPhosphorylated epidermal growth factor receptorCommonest adverse eventsP16+ diseaseProgression-free survivalImmune checkpoint therapyP16-positive tumorsPlatinum-based chemotherapyPrimary tumor locationPhase 2 trialPhase II trialSquamous cell cancerPost-treatment biopsiesTrials of chemotherapyEGFR inhibitor treatmentSWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation.
Reckamp K, Redman M, Dragnev K, Khalil M, Henick B, Moon J, Ahmadzai P, LeBlanc M, Carrizosa D, Herbst R, Blanke C, Gray J. SWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation. Journal Of Clinical Oncology 2025, 43: 11016-11016. DOI: 10.1200/jco.2025.43.16_suppl.11016.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerStandard of careOverall survivalPD-(L)1Randomized phase III trialPhase II randomized studyPlatinum-based therapyTreated with immunotherapyPhase III trialsCell lung cancerYears of ageInhibitor therapyIII trialsStudy drugConcomitant medicationsOS endpointSafety profileToxicity profileAdverse eventsEffective therapyLung cancerBlack patientsReal-world practiceLaboratory assessmentNeoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Sadek N, Hamon P, Hennequin C, Devraj V, Thanigaimani P, Uldrick T, Miller E, Lowy I, Doroshow D, Tabrizian P, Schwartz M, Merad M, Marron T. Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16320.Peer-Reviewed Original ResearchTreatment-related adverse eventsRelapse-free survivalOverall response rateAnti-PD-1Single-institution experienceResectable hepatocellular carcinomaNeoadjuvant immunotherapyHepatocellular carcinomaAdverse eventsTumor necrosisPathological responseSingle-agent anti-PD-1Early-stage hepatocellular carcinomaEarly-phase clinical trialsGrade 3 hepatitisAdvanced hepatocellular carcinomaDelay of surgerySurvival of patientsCombination immunotherapyNeoadjuvant settingAdjuvant immunotherapyResected tumorMetastatic diseaseImmunotherapy regimensNeoadjuvant nivolumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply